The Danish antibody pioneer Symphogen A/S is to be acquired by Laboratoires Servier, culminating more than two years of close partnership between the two companies focused on oncology. The value of the transaction was not disclosed however the sums already committed by Servier for access to Symphogen’s portfolio are considerable. Potential milestone payments under the companies’ existing partnership amount to DKK 9 billion (€1.2 billion).
